Mammoth Biosciences looks to build next-generation CRISPR toolbox

June 7, 2022 -- This month marks the 10th anniversary of the development of CRISPR as a genome-editing tool, which earned Jennifer Doudna, PhD, and Emmanuelle Charpentier, PhD, the 2020 Nobel Prize in Chemistry. While the technology is fairly new, it has made major strides over the past decade, according to Mammoth Biosciences co-founder and CEO Trevor Martin.

Ten years down the road, Martin told that CRISPR has transitioned from basic science to a widely adopted research tool and has emerged as a potentially transformative therapeutic modality.

"There's been a ton of progress in a relatively short amount of time compared to other emerging technologies, whether that's moving things closer to the clinic or further developments of the technology itself," Martin said. "It's still really early days in terms of potential."

While the Cas9 protein is what Mammoth Biosciences co-founder and CRISPR pioneer Doudna made famous a decade ago, the biotech company is looking to broaden its toolbox of next-generation CRISPR systems. Martin said Mammoth is "excited about expanding the potential of CRISPR" with non-Cas9 proteins.

Mammoth's platform leverages novel Cas enzymes, including Cas14 and Casɸ, which are designed to create CRISPR-based therapeutics and diagnostics for a range of diseases. In addition to their ultra-small size, Mammoth contends these enzymes are more temperature stable and capable of high-fidelity editing.

Watch the video below to learn more.

Graphite Bio sees its gene editing tech as step above CRISPR
While the use of CRISPR is an effective gene editing tool on its own, Dr. Josh Lehrer, CEO of Graphite Bio, contends that the technology doesn’t correct...
CRISPR technique may lead to hypoallergenic cats
Love cats but have allergies? Rejoice! Scientists have demonstrated that CRISPR gene editing of the cat allergen, Felis domesticus allergen I, could bring...
Intellia, ONK Therapeutics advance CRISPR-edited NK cell therapies for cancer
Intellia Therapeutics and ONK Therapeutics have entered into a licensing and collaboration agreement to develop innovative cancer treatments by combining...
CRISPR Therapeutics, ViaCyte dose type 1 diabetes patient with new cell therapy
CRISPR Therapeutics and ViaCyte have dosed the first patient with VCTX210 in a phase I clinical trial for the treatment of type 1 diabetes.
Sarepta Therapeutics, GenEdit collaborate on gene editing therapies
Sarepta Therapeutics and GenEdit have released results from a research collaboration and option agreement under which the companies are employing GenEdit's...
Bayer, Mammoth Biosciences collaborate on gene editing technology
Bayer and Mammoth Biosciences have entered into a strategic collaboration and option agreement for the use of Mammoth's CRISPR systems to develop in vivo...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter